Quantcast

Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher


Shutterstock photo

Syros Pharmaceuticals, Inc. SYRS was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $8.45 -$15.40 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Syros Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Syros Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Syros Pharmaceuticals, Inc. Price

Syros Pharmaceuticals, Inc. Price | Syros Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical sector is Akari Therapeutics PLC AKTX which carries a Zacks Rank #1 (Strong Buy).You can see  the complete list of today's Zacks #1 Rank stocks here .

Is SYRS going up? Or down? Predict to see what others think: Up or Down .

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Syros Pharmaceuticals, Inc. (SYRS): Free Stock Analysis Report

Akari Therapeutics PLC (AKTX): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Investing , Investing Ideas , Stocks
Referenced Symbols: SYRS , AKTX




More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research












Research Brokers before you trade

Want to trade FX?